Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06625398 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Study acronym: REVEAL-2
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 37 → 60 locationsv12
  2. Primary endpoint revised
    • Enrollment target: estimated 195 to confirmed 204
    • Primary completion date changed from estimate of Apr 1, 2026 to Mar 4, 2026
    • Secondary endpoints: 4 to 6
    v11
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 37 of 37 sites
    v10
  4. Study sites: 36 to 37v9
  5. Enrollment target: 126 to 195v8 Show 4 more changesShow less
    • Study sites: 35 to 36
    • Eligibility criteria expanded, about 48 words
    • Secondary endpoints: 5 to 4
    • Study description expanded, about 6 words
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 34 to 35v7
  2. Study sites: 17 to 34v6
  3. Study sites: 10 to 17v5
  4. Study sites revised (10)v4
  5. Study sites: 7 to 10v3
  6. Study sites: 2 to 7v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Trial Details
NCT Number NCT06625398
Lead Sponsor Viridian Therapeutics, Inc.
Conditions
(from sponsor)		 Thyroid Eye Disease
Related terms Graves Ophthalmopathy
Enrollment 204 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov